Results 111 to 120 of about 14,613 (227)

Delayed diagnosis of Brugada syndrome in a patient with aborted sudden cardiac death and initial negative flecainide challenge

Clinical Case Reports, 2017
Key Clinical Message A negative flecainide challenge does not rule out Brugada syndrome even in the presence of nonfatal cardiac arrest as the first manifestation of the disease.
Samuel Chauveau, Olivier Le Vavasseur, Philippe Chevalier   +2 more
doaj   +1 more source

Rapid and inexpensive high-performance liquid chromatographic method for the quantification of flecainide in serum [PDF]

, 1988
H.M. Liebich, Mayer, F., Kühlkamp, V., K.M. Ress, Krämer, Bernhard K., F. Mayer, L. Seipel, Liebich, H. M., Seipel, L., B.K. Krämer, Ress, K. M., Becker, J. U., J.U. Becker, V. Kühlkamp, Risler, T., T. Risler   +15 more
core   +1 more source

Effects of MiRP1 and DPP6 beta-subunits on the blockade induced by flecainide of Kv4.3/KChIP2 channels

, 2008
Background and purpose: The human cardiac transient outward potassium current (Ito) is believed to be composed of the pore-forming Kv4.3 alpha-subunit, coassembled with modulatory beta-subunits as KChIP2, MiRP1 and DPP6 proteins.
Vaquero González, Luis Miguel, Tamargo Menéndez, Juan, Ravens, Ursula, Delpón Mosquera, María Eva, Wettwer, Eric, Caballero Collado, Ricardo, Gómez García, Ricardo, Núñez Fernández, Lucía, Radicke, Susanne   +8 more
core   +1 more source

Flecainide acetate for the treatment of atrial and ventricular arrhythmias

, 2013
INTRODUCTION: Flecainide is a class Ic antiarrhythmic agent available in Europe since 1982. The clinical development program of flecainide provided good data on its antiarrhythmic effect for the prevention of ventricular and supraventricular arrhythmias.
Kirchhof, Paulus; id_orcid, Fabritz, Larissa; id_orcid, Breithardt, Günter, Apostolakis, Stavros, Tebbe, Ulrich, Oeff, Michael   +5 more
core   +1 more source

Flecainide in patients with arrhythmic mitral valve syndrome - a case series.

Heart Rhythm, 2022
E. Aabel, L. Dejgaard, M. Chivulescu, T. Helle-Valle, T. Edvardsen, N. Hasselberg, F. Hegbom, Øyvind H. Lie, K. Haugaa   +8 more
semanticscholar   +1 more source

Antiarrhythmic treatment with flecainide (Tambocor). Clinical experience from 107 patients

, 1990
Udgivelsesdato: 1990-nullThe long-term clinical effect of oral flecainide treatment was evaluated in 107 pts (10-82 yrs). Indications for treatment were: atrial fibrillation 38%, atrial flutter 16%, ventricular tachycardia 24%, ventricular ectopic beats ...
Mickley, H, Pless, P, Møller, M, Frandsen, F   +3 more
core   +1 more source

Pediatric flecainide pharmacogenomics: a roadmap to delivering precision-based care to pediatrics arrhythmias

Frontiers in Pharmacology
Flecainide acetate is a Class 1c anti-arrhythmic with a potent sodium voltage gated channel blockade which is utilized for the second-line treatment of tachyarrhythmias in children and adults.
Ronald Palmen, Mollie Walton, Mollie Walton, Mollie Walton, Jonathan Wagner, Jonathan Wagner, Jonathan Wagner   +6 more
doaj   +1 more source

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

New England Journal of Medicine, 1991
D. Echt, P. Liebson, L. Mitchell, R. Peters, D. Obias-Manno, A. H. Barker, D. Arensberg, A. Baker, L. Friedman, H. Greene   +9 more
semanticscholar   +1 more source

The Successful Management of a Flecainide-Induced Ventricular Storm

INTRODUCTION: Flecainide is a first line rhythm control class 1C antidysrhythmic used in atrial fibrillation in patients without left ventricular dysfunction A rare side effect of the medication is inducing ventricular tachycardia (VT) as a result of the
Marchewka, TIffany, Kenney, Catalin Vic, Heal, Kathryn   +2 more
core   +1 more source

Flecainide: long-term treatment using a reduced dosing schedule.

, 1985
Flecainide was initially prescribed at a dose of 200 mg twice daily, but after early toxicity in patients with ventricular tachycardia (VT), the dosage was reduced to 100 mg twice daily.
Torres, V, O\u27Gallagher, D, Somberg, J C, Flowers, D, Miura, D   +4 more
core   +1 more source